Adagene Inc
978
Company Profile
Business description
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.
Contact
Xinghu Street, Suzhou Industrial Park
4th Floor, Building C14, No. 218
Jiangsu Province
Suzhou215123
CHNT: +86 51287773632
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
138
Stocks News & Analysis
stocks
10 best US growth stocks to buy for the long term
The stocks of these high-quality growth companies look undervalued today.
stocks
Higher fair value for overvalued ASX tech share
Underlying secular growth stronger than we thought.
stocks
Nvidia: Collaboration with Intel might bring some goodwill with the US
We doubt the $5 billion is meaningful enough to force Nvidia to use Intel, either for core products or even for the chips in collaboration.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,102.10 | 11.70 | 0.13% |
| CAC 40 | 7,830.11 | 23.48 | -0.30% |
| DAX 40 | 23,527.05 | 112.36 | -0.48% |
| Dow JONES (US) | 46,401.60 | 86.33 | 0.19% |
| FTSE 100 | 9,226.68 | 10.01 | 0.11% |
| HKSE | 26,344.14 | 200.96 | -0.76% |
| NASDAQ | 22,767.90 | 136.42 | 0.60% |
| Nikkei 225 | 45,493.66 | 447.85 | 0.99% |
| NZX 50 Index | 13,141.54 | 90.12 | -0.68% |
| S&P 500 | 6,691.69 | 27.33 | 0.41% |
| S&P/ASX 200 | 8,810.90 | 11.40 | 0.13% |
| SSE Composite Index | 3,828.58 | 8.49 | 0.22% |